Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.
about
Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulInfluence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureusQuinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibioticsBactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicatorActivities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal.Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antiQuinupristin-dalfopristin: an overview.Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection modelsCommonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.What do we really know about antibiotic pharmacodynamics?Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics.Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis.Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.Current perspectives on glycopeptide resistance.Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics.Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study.Tuberculosis: a search for novel therapy starting with natural products.Diminished killing of pneumococci by pristinamycin demonstrated by time-kill studiesDistribution, characterization and genetic bases of erythromycin resistance in staphylococci and enterococci originating from livestock.Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.
P2860
Q28367434-38571BAC-CD1E-44E9-A97F-2A119C9C95F7Q28379547-94CC0E48-C933-4AC5-8A6C-54417029DF69Q33695596-ECBDF57D-8377-4E51-A216-5E1DD0B6CFF9Q33700022-2E748886-4C1E-410D-A2EC-74EE9BD7C1E7Q33979371-B394838F-3785-47BA-BB29-EB511805894AQ33979939-804B6B93-1FE8-4B55-AE24-145A56F78A33Q33980853-B72B643B-2374-4BEE-8083-7DC9D1C2AF14Q33981950-03E1E370-384F-415F-B1A9-0BB2014BB1DAQ33983015-AEFB4788-B015-42AA-BC01-3462D66536ECQ34113421-273255F0-2C92-4008-9BEA-E2AC3E220D6FQ34113774-E94705BB-9EAC-4BC7-8598-0BD15F5E3059Q34301626-0210E9D1-BB1F-43C5-93E9-951384BB09E9Q34437719-F10CBA0D-062D-42B7-BD7F-F41913C1F006Q34443407-E4096823-C70D-49DD-89AF-DEC440E6B966Q35128993-9B2FF56A-3FE2-41CF-AC1F-7E9954C7D484Q35135710-F2666A53-E7D2-4E8E-AD65-45DA13B31714Q35136776-A064C017-290C-4D1B-A307-BCC5E5F71D85Q35139489-CCEB2C66-17F3-414E-9EC2-F1F94E77C0F4Q35368590-65E56F8A-B996-4104-B37F-0FC9BE5F14E3Q35376362-EB669D12-869A-44EB-86BE-B0054EDEF3D5Q38093135-A42A7A30-BC1F-4292-8196-227C5CF46FA3Q39558239-F49748CE-05BA-41C0-ADFC-12E35F2CF9FDQ39651450-19A638C3-829C-4DA1-B55C-BF81C9806342Q39652231-ACE23DB0-0B68-41D3-91F1-B9F00B07C922Q42538050-A748F145-A279-4B0D-880A-2954FF510C86Q42728978-70B400C5-6097-41A7-BCD2-EFA91BCD1A27Q43229893-0FA73FC9-A086-46F0-AF86-DC88CBA4EB9AQ53854341-97ADA972-8B56-4EDA-B3C5-5B25D291B51B
P2860
Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Critical influence of resistan ...... due to Staphylococcus aureus.
@ast
Critical influence of resistan ...... due to Staphylococcus aureus.
@en
type
label
Critical influence of resistan ...... due to Staphylococcus aureus.
@ast
Critical influence of resistan ...... due to Staphylococcus aureus.
@en
prefLabel
Critical influence of resistan ...... due to Staphylococcus aureus.
@ast
Critical influence of resistan ...... due to Staphylococcus aureus.
@en
P2093
P2860
P356
P1476
Critical influence of resistan ...... due to Staphylococcus aureus.
@en
P2093
Leclercq R
Saint-Julien L
P2860
P304
P356
10.1128/AAC.39.2.400
P407
P577
1995-02-01T00:00:00Z